/images/ppid_59c68470-image-176639509815174675.webp)
What is the story about?
Emcure Pharmaceuticals Ltd.
has launched Poviztra, a semaglutide injection for chronic weight management, marking its entry into the fast-growing obesity and metabolic health segment, the company said on Monday, December 22.
In an exchange filing, Emcure said it is the first Indian company to exclusively distribute and commercialise Poviztra, positioned as a second brand of Novo Nordisk’s semaglutide for weight management. The drug will be available across India in a once-per-week pen device in five dosage strengths, with prices starting at ₹8,790 per month for four weekly doses.
Citing India's obesity crisis, Satish Mehta - CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “The introduction of Poviztra®
marks an important step in expanding equitable access to scientifically validated weight-management solutions," as nearly 254 million people are living with generalised obesity, with an additional 351 million people living with abdominal obesity.
Semaglutide is used as an adjunct to diet and physical activity for adults with obesity or overweight conditions accompanied by related health risks such as diabetes and hypertension. The formulation has also been approved to reduce the risk of major cardiovascular events in certain high-risk patients, the company said.
Emcure noted that the launch is backed by extensive global clinical data on semaglutide, including large late-stage trials that have shown significant weight reduction in patients. The molecule has been in global use for nearly a decade.
"Through our strong distribution capabilities and pan-India reach, we aim to ensure that more patients can benefit from advanced therapies like semaglutide,” Mehta added.
The launch comes as Indian drugmakers increasingly expand into lifestyle and chronic therapies amid rising demand for treatments targeting obesity and related metabolic disorders.
Emcure Pharmaceuticals, headquartered in Pune, has operations across more than 70 countries. It reported a 25.1% year-on-year rise in consolidated net profit to ₹243 crore for the September quarter, from ₹194 crore in the same period last year.
The pharma company's revenue from operations grew 13.4% year-on-year to ₹2,269.8 crore from ₹2,001.9 crore in Q2 FY25, and EBITDA rose 25% to ₹475.4 crore from ₹380.3 crore in the year-ago quarter, while EBITDA margin improved to 21% from 19% a year earlier, aided by better product mix and cost efficiencies.
Shares of Emcure Pharmaceuticals were trading 0.32% down at ₹1,380.50 as of 1:45 pm. The stock has fallen 5.47% in this calendar year.
In an exchange filing, Emcure said it is the first Indian company to exclusively distribute and commercialise Poviztra, positioned as a second brand of Novo Nordisk’s semaglutide for weight management. The drug will be available across India in a once-per-week pen device in five dosage strengths, with prices starting at ₹8,790 per month for four weekly doses.
Citing India's obesity crisis, Satish Mehta - CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “The introduction of Poviztra®
marks an important step in expanding equitable access to scientifically validated weight-management solutions," as nearly 254 million people are living with generalised obesity, with an additional 351 million people living with abdominal obesity.
Semaglutide is used as an adjunct to diet and physical activity for adults with obesity or overweight conditions accompanied by related health risks such as diabetes and hypertension. The formulation has also been approved to reduce the risk of major cardiovascular events in certain high-risk patients, the company said.
Emcure noted that the launch is backed by extensive global clinical data on semaglutide, including large late-stage trials that have shown significant weight reduction in patients. The molecule has been in global use for nearly a decade.
"Through our strong distribution capabilities and pan-India reach, we aim to ensure that more patients can benefit from advanced therapies like semaglutide,” Mehta added.
The launch comes as Indian drugmakers increasingly expand into lifestyle and chronic therapies amid rising demand for treatments targeting obesity and related metabolic disorders.
Emcure Pharmaceuticals, headquartered in Pune, has operations across more than 70 countries. It reported a 25.1% year-on-year rise in consolidated net profit to ₹243 crore for the September quarter, from ₹194 crore in the same period last year.
The pharma company's revenue from operations grew 13.4% year-on-year to ₹2,269.8 crore from ₹2,001.9 crore in Q2 FY25, and EBITDA rose 25% to ₹475.4 crore from ₹380.3 crore in the year-ago quarter, while EBITDA margin improved to 21% from 19% a year earlier, aided by better product mix and cost efficiencies.
Shares of Emcure Pharmaceuticals were trading 0.32% down at ₹1,380.50 as of 1:45 pm. The stock has fallen 5.47% in this calendar year.
/images/ppid_59c68470-image-176639503088098432.webp)
/images/ppid_59c68470-image-176613015365770139.webp)
/images/ppid_a911dc6a-image-176612612758376828.webp)
